Royalty Pharma (RPRX) EBIT Margin (2019 - 2026)

Royalty Pharma has disclosed EBIT Margin across 8 years of filings, most recently posting 89.29% for Q1 2026.

• EBIT Margin for Q1 2026 came in at 89.29%, down 472.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 65.08% (down 1886.0% YoY), and the FY2025 annual result was 65.58%, up 848.0% from the prior year.
• EBIT Margin came in at 89.29% for Q1 2026 at Royalty Pharma, up from 62.44% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 130.17% in Q3 2024 to a low of 85.31% in Q4 2022.
• The 5-year median for EBIT Margin is 60.9% (2024), against an average of 52.09%.
• Across the five-year window, EBIT Margin sank 11196 bps in 2022 and soared 18814 bps in 2023, its largest moves.
• Royalty Pharma's EBIT Margin stood at 85.31% in 2022, then surged by 221 bps to 102.82% in 2023, then tumbled by 41 bps to 60.9% in 2024, then increased by 3 bps to 62.44% in 2025, then surged by 43 bps to 89.29% in 2026.
• The last three EBIT Margin figures came in at 89.29% (Q1 2026), 62.44% (Q4 2025), and 70.11% (Q3 2025), per Business Quant data.